Rizatriptan Benzoate Tablet, Orally Disintegrating
Product Images NDC 71335-2982

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 71335-2982). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label (Lbl713352982)

Label (Lbl713352982)
Label for Rizatriptan Benzoate Orally Disintegrating Tablets USP, 10 mg strength, in a package containing 9 tablets. The label includes NDC 71335-2982-1, indicates oral administration, and features the Bryant Ranch Prepack logo. Manufactured by Aurobindo Pharma Limited and repackaged by Bryant Ranch Prepack, Inc., Burbank, CA.*
FDA Label Image

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)
A Kaplan-Meier plot titled 'Estimated Probability of Achieving an Initial Headache Response by 2 Hours in Pooled Studies 1, 2, 3, and 4.' It compares estimated probabilities of headache response over 2 hours post-dose for placebo, Rizatriptan Benzoate Tablets 5 mg, and 10 mg. The plot shows increasing response probabilities with higher doses over time.*
FDA Label Image

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 1, 2, 3, And 4††† (Rizatriptan Fig2)

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 1, 2, 3, And 4††† (Rizatriptan Fig2)
Kaplan-Meier curve chart depicting the estimated probability over 24 hours that patients take a second dose of Rizatriptan Benzoate tablets (5 mg and 10 mg) or placebo for migraine relief. The x-axis represents hours post-dose and the y-axis the estimated probability of remediation or rescue. Three lines show differing probabilities for placebo, 5 mg, and 10 mg Rizatriptan Benzoate tablets.*
FDA Label Image

Figure 3: Estimated Probability Of Achieving An Initial Headache Response With Rizatriptan Benzoate Orally Disintegrating Tablets By 2 Hours In Pooled Studies 5 And 6‡ (Rizatriptan Fig3)

Figure 3: Estimated Probability Of Achieving An Initial Headache Response With Rizatriptan Benzoate Orally Disintegrating Tablets By 2 Hours In Pooled Studies 5 And 6‡ (Rizatriptan Fig3)
A Kaplan-Meier plot showing the estimated probability of achieving an initial headache response within 2 hours after dosing with Rizatriptan Benzoate orally disintegrating tablets at 5 mg and 10 mg doses compared to placebo. The graph's x-axis represents hours post-dose, and the y-axis shows the estimated probability of response.*
FDA Label Image

Figure 4: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Orally Disintegrating Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 5 And 6‡‡ (Rizatriptan Fig4)

Figure 4: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Orally Disintegrating Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 5 And 6‡‡ (Rizatriptan Fig4)
A Kaplan-Meier plot showing the estimated probability over 24 hours that patients take a second dose of Rizatriptan Benzoate orally disintegrating tablets (5 mg and 10 mg) or placebo for migraine treatment. The chart compares the probabilities of rescue medication use between placebo, 5 mg, and 10 mg doses post-initial treatment in pooled clinical studies.*
FDA Label Image

Figure 5: Observed Percentage Of Patients Reporting No Headache Pain By 2 Hours Post-dose In Study 7 (Rizatriptan Fig5)

Figure 5: Observed Percentage Of Patients Reporting No Headache Pain By 2 Hours Post-dose In Study 7 (Rizatriptan Fig5)
A line graph titled 'Observed Percentage of Patients Reporting No Headache Pain by 2 Hours Post-Dose in Study 7.' It compares percentage of patients without headache pain over time (0.5 to 2 hours) after dosing with Rizatriptan Benzoate orally disintegrating tablets versus placebo. The graph shows increasing percentages over time, with Rizatriptan Benzoate consistently higher than placebo.*
FDA Label Image

Chemical Structure (Rizatriptan Str)

Chemical Structure (Rizatriptan Str)
Chemical structure of Rizatriptan Benzoate depicted as a two-part molecular formula showing the rizatriptan molecule with its characteristic rings and side chains, alongside the benzoate component.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.